Physician profile
Heather Branch
NPI 1144732983
$1,968.25
in general payments reported to CMS, 2019-2025
22 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $121 · 2023: $300 · 2024: $722 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $364.12 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Pfizer INC. | $228.24 | 2021-2025 | |
| Novo Nordisk INC | $220.17 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $195.66 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $178.35 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $157.06 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.00 | 2021-2025 | |
| Lilly USA, LLC | $110.59 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $65.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $50.34 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $50.03 | 2023-2025 | Rexulti |
| Corium, LLC | $47.99 | 2022-2023 | Azstarys |
| Noven Therapeutics, LLC | $21.12 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $20.41 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.78 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $19.49 | 2022 | |
| Organon LLC | $19.30 | 2024-2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $16.82 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.73 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $13.53 | 2025 | Vaxelis, Capvaxive, M-M-R II |
| Phathom Pharmaceuticals, INC. | $12.79 | 2025 | Voquezna |
| Gilead Sciences, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.